Management der hochgradigen Neoplasie der Barrett-Schleimhaut (High Grade Dysplasia)

Die hochgradige Neoplasie der Barrett-Schleimhaut (HGD) ist definiert als eine intraepitheliale Neoplasie im Rahmen der Metaplasie-Dysplasie-Karzinom-Sequenz des Barrett-Karzinoms. Der naturliche zeitliche Verlauf der malignen Entartung der HGD ist unbekannt, so dass Aussagen zum Risiko der Entwicklung eines invasiven Karzinoms nur eingeschrankt moglich sind. Das zentrale Problem der Behandlung der HGD liegt in den bisher nur unvollkommenen endoskopischen und histopathologischen Nachweismoglichkeiten, die die Sicherung der HGD innerhalb einer Barrett-Metaplasie erschweren. Trotz erheblicher Fortschritte bei der endoskopischen Identifikation der Lasionen sowie verbesserter Nachweisverfahren auf histologischer Ebene bleibt die Diagnostik der HGD kontrovers. Die prognostischen und diagnostischen Unsicherheiten spiegeln sich in der Breite der zur Verfugung stehenden therapeutischen Optionen wider. Diese reichen von regelmasiger endoskopischer Kontrolle uber Ablationsverfahren bis hin zur komplexen thorakoabdominalen Osophagusresektion. In der vorliegenden Arbeit werden aktuelle diagnostische und therapeutische Strategien zusammenfasst und ein Algorithmus zur Behandlung der HGD erarbeitet. High-grade neoplasia of Barrett's esophagus (HGD) is defined as an intraepithelial neoplastic condition occurring within the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's carcinoma. As the natural history of HGD remains unknown, a patient's actual risk for the development of invasive malignancy is difficult to define. Main drawbacks of the management of HGD are the shortcomings of the endoscopic and histologic diagnostic tools. Despite recent advances of diagnostic tests, the identification of HGD remains controversial. Diagnostic and prognostic uncertainties are reflected by the multitude of therapeutic options that range from endosocopic surveillance to complex thoracoabdominal surgery. The present paper resumes actual diagnostic and therapeutic strategies, an algorithm for the treatment of HGD is proposed by the authors.

[1]  Gregory Zuccaro,et al.  Optical coherence tomography in the gastrointestinal tract. , 2004, Gastrointestinal endoscopy clinics of North America.

[2]  Kenneth K Wang,et al.  Photodynamic therapy in Barrett's esophagus. , 2003, Gastrointestinal endoscopy clinics of North America.

[3]  L. Gossner,et al.  Chromoscopy of intestinal metaplasia in Barrett's esophagus. , 2002, Endoscopy.

[4]  P. Chandrasoma,et al.  Detection of Barrett's epithelium by acoustic microscopy. , 2002, Ultrasound in medicine & biology.

[5]  J. Collard.  High-grade dysplasia in Barrett's esophagus. The case for esophagectomy. , 2002, Chest surgery clinics of North America.

[6]  A. Sonnenberg,et al.  Long-term nonsurgical management of Barrett's esophagus with high-grade dysplasia. , 2001, Gastroenterology.

[7]  K. Badizadegan,et al.  Fluorescence, reflectance, and light-scattering spectroscopy for evaluating dysplasia in patients with Barrett's esophagus. , 2001, Gastroenterology.

[8]  J K Greenson,et al.  Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. , 2001, Human pathology.

[9]  M. Feith,et al.  Limited Resection for Early Adenocarcinoma in Barrett’s Esophagus , 2000, Annals of surgery.

[10]  J. Goldblum,et al.  The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression , 2000, American Journal of Gastroenterology.

[11]  J. J. Padilla,et al.  Endoscopic ultraviolet-induced autofluorescence spectroscopy of the esophagus: tissue characterization and potential for early cancer diagnosis. , 2000, Endoscopy.

[12]  U Seitz,et al.  In vivo endoscopic optical coherence tomography of esophagitis, Barrett's esophagus, and adenocarcinoma of the esophagus. , 2000, Endoscopy.

[13]  B. Overholt,et al.  Results of photodynamic therapy for ablation of dysplasia and early cancer in Barrett's esophagus and effect of oral steroids on stricture formation , 2000, American Journal of Gastroenterology.

[14]  Prateek Sharma,et al.  Long-term follow-up of Barrett's high-grade dysplasia , 2000, American Journal of Gastroenterology.

[15]  M F Dixon,et al.  The Vienna classification of gastrointestinal epithelial neoplasia , 2000, Gut.

[16]  Gary Longton,et al.  Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets , 2000, American Journal of Gastroenterology.

[17]  T. Demeester,et al.  Columnar mucosa and intestinal metaplasia of the esophagus: fifty years of controversy. , 2000, Annals of surgery.

[18]  E. G. Hahn,et al.  Photodynamic destruction of high grade dysplasia and early carcinoma of the esophagus after the oral administration of 5‐aminolevulinic acid , 1999, Cancer.

[19]  H. Feußner,et al.  Bile reflux in benign and malignant barrett’s esophagus: Effect of medical acid suppression and nissen fundoplication , 1998, Journal of Gastrointestinal Surgery.

[20]  R. Sampliner,et al.  Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus , 1998, American Journal of Gastroenterology.

[21]  L. Gossner,et al.  Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. , 1998, Gastroenterology.

[22]  G. Triadafilopoulos,et al.  Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus , 1998, American Journal of Gastroenterology.

[23]  A. Hölscher,et al.  Early adenocarcinoma in Barrett's oesophagus , 1997, The British journal of surgery.

[24]  H. Barr,et al.  Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX , 1996, The Lancet.

[25]  R. H. Riddell.  Premalignant and early malignant lesions in the gastrointestinal tract: definitions, terminology, and problems. , 1996, The American journal of gastroenterology.

[26]  R. Sampliner,et al.  Diagnostic inconsistencies in Barrett's esophagus , 1994 .

[27]  J. Jansen,et al.  Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety , 1994, Annals of Internal Medicine.

[28]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[29]  Prateek Sharma.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. , 2002, Gastrointestinal endoscopy.

[30]  Y. Kajiyama,et al.  Esophagectomy without thoracotomy with vagal preservation. , 1994, Journal of the American College of Surgeons.

[31]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[32]  B. Reid,et al.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. , 1988, Gastroenterology.